Researchers at the University of Missouri School of Medicine in Columbia tested an FDA-approved medical device designed to speed up autism diagnoses in areas with limited access to specialty care.
The tool uses AI to analyze patient data and produce a positive, negative or indeterminate autism diagnosis, according to a Dec. 18 news release from the university.
The team integrated the tool, CanvasDx, into Missouri’s ECHO Autism program, which trains primary care clinicians to deliver autism care in underserved areas. In a study of 80 children, CanvasDx delivered determinate results in 52% of cases and aligned with clinician diagnoses, yielding no false positives or false negatives.
Travel to specialty care centers averaged 97 miles, but the study found that using CanvasDx locally allowed families to receive a diagnosis five to seven months sooner.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
